On the Record 08 30 2022

“Pfizer and Moderna have a lot of market power here. The federal government being able to negotiate on behalf of the entire country has some real value, in terms of getting prices that the private insurance companies might not be able to. I think we’ll probably end up paying higher prices.”   —Loren Adler, an economist and associate director of the USC-Brookings Schaeffer Initiative for Health Policy, spoke with AIS’s Radar on Drug Benefits about how the health care industry will be impacted when the federal government stops purchasing COVID-19 vaccines and therapeutics.

 

Subscribers may read the Radar on Drug Benefits article in which this quote appeared online. Learn more about subscribing to AIS Health's publications.    SHAPE  \* MERGEFORMAT